Cancer Research Cell Death Mechanisms and Cancer Therapy  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 59, 377-381, January 1, 1999]
© 1999 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Utsumi, T.
Right arrow Articles by Harada, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Utsumi, T.
Right arrow Articles by Harada, N.
[Cancer Research 59, 377-381, January 15, 1999]
© 1999 American Association for Cancer Research


Endocrinology

Steroid Sulfatase Expression Is an Independent Predictor of Recurrence in Human Breast Cancer1

Toshiaki Utsumi, Noriko Yoshimura, Shinji Takeuchi, Jiro Ando, Morito Maruta, Kotaro Maeda and Nobuhiro Harada2

Departments of Surgery [T. U., M. M., K. M.] and Biochemistry [N. Y., N. H.], Fujita Health University School of Medicine, Toyoake, Aichi 470-1192; Marumo Hospital, Nagoya, Aichi 465-0024 [S. T.]; and Department of Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi 320-0834 [J. A.], Japan

Steroid sulfatase (STS) hydrolyzes several sulfated steroids such as estrone sulfate, dehydroepiandrosterone sulfate, and cholesterol sulfate. In the present study, we have measured STS mRNA levels in 97 breast cancers by reverse transcription-PCR using a fluorescent primer in the presence of an internal standard RNA and evaluated its association with disease-free and overall survival. The median value was 728.0 amol/ng RNA (range, 0–11,778 amol/ng RNA). Levels were significantly higher in tumors demonstrating lymph node metastasis than in those without nodal involvement (P = 0.033) and in patients who experienced a recurrence during the follow-up period (mean, 40.8 months; median, 39 months) compared with those with no evidence of further disease (mean, 49.2 months; median, 48 months; P = 0.029). No significant associations were found between STS mRNA expression and age, menopausal status, tumor size, histological grade, estrogen receptor status, or postoperative adjuvant therapy. High levels of STS mRNA proved to be a significant predictor of reduced relapse-free survival as a continuous variable (log STS mRNA; P = 0.028). As a dichotomous variable with an optimized cutoff point of 1,240 amol/ng RNA, expression was also associated with a significantly shorter relapse-free survival rate (P = 0.002), but no significant correlation was found between the STS mRNA level and overall survival. Expression was found to be an independent factor for predicting relapse-free survival on multivariate analysis. The results thus support a putative role of STS in breast cancer growth and metastasis.




This article has been cited by other articles:


Home page
Anticancer ResHome page
M. KULENDRAN, M. SALHAB, and K. MOKBEL
Oestrogen-Synthesising Enzymes and Breast Cancer
Anticancer Res, April 1, 2009; 29(4): 1095 - 1109.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
S. J. Stanway, P. Delavault, A. Purohit, L. W. L. Woo, C. Thurieau, B. V. L. Potter, and M. J. Reed
Steroid Sulfatase: A New Target for the Endocrine Therapy of Breast Cancer
Oncologist, April 1, 2007; 12(4): 370 - 374.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. J. Stanway, A. Purohit, L.W. L. Woo, S. Sufi, D. Vigushin, R. Ward, R. H. Wilson, F. Z. Stanczyk, N. Dobbs, E. Kulinskaya, et al.
Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor
Clin. Cancer Res., March 1, 2006; 12(5): 1585 - 1592.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
N. Honma, K. Takubo, M. Sawabe, T. Arai, F. Akiyama, G. Sakamoto, T. Utsumi, N. Yoshimura, and N. Harada
Estrogen-Metabolizing Enzymes in Breast Cancers from Women over the Age of 80 Years
J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 607 - 613.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
T. Suzuki, Y. Miki, Y. Nakamura, T. Moriya, K. Ito, N. Ohuchi, and H. Sasano
Sex steroid-producing enzymes in human breast cancer
Endocr. Relat. Cancer, December 1, 2005; 12(4): 701 - 720.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Ishibashi, T. Suzuki, S. Suzuki, T. Moriya, C. Kaneko, T. Nakata, M. Sunamori, M. Handa, T. Kondo, and H. Sasano
Estrogen Inhibits Cell Proliferation through In situ Production in Human Thymoma
Clin. Cancer Res., September 15, 2005; 11(18): 6495 - 6504.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
M. J. Reed, A. Purohit, L. W. L. Woo, S. P. Newman, and B. V. L. Potter
Steroid Sulfatase: Molecular Biology, Regulation, and Inhibition
Endocr. Rev., April 1, 2005; 26(2): 171 - 202.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Utsunomiya, K. Ito, T. Suzuki, T. Kitamura, C. Kaneko, T. Nakata, H. Niikura, K. Okamura, N. Yaegashi, and H. Sasano
Steroid Sulfatase and Estrogen Sulfotransferase in Human Endometrial Carcinoma
Clin. Cancer Res., September 1, 2004; 10(17): 5850 - 5856.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Suzuki, T. Nakata, Y. Miki, C. Kaneko, T. Moriya, T. Ishida, S. Akinaga, H. Hirakawa, M. Kimura, and H. Sasano
Estrogen Sulfotransferase and Steroid Sulfatase in Human Breast Carcinoma
Cancer Res., June 1, 2003; 63(11): 2762 - 2770.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Miyoshi, A. Ando, S. Hasegawa, M. Ishitobi, T. Taguchi, Y. Tamaki, and S. Noguchi
High Expression of Steroid Sulfatase mRNA Predicts Poor Prognosis in Patients with Estrogen Receptor-positive Breast Cancer
Clin. Cancer Res., June 1, 2003; 9(6): 2288 - 2293.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
Y. Miki, T. Nakata, T. Suzuki, A. D. Darnel, T. Moriya, C. Kaneko, K. Hidaka, Y. Shiotsu, H. Kusaka, and H. Sasano
Systemic Distribution of Steroid Sulfatase and Estrogen Sulfotransferase in Human Adult and Fetal Tissues
J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5760 - 5768.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. M. Harris, R. H. Waring, C. J. Kirk, and P. J. Hughes
Sulfation of "Estrogenic" Alkylphenols and 17beta -Estradiol by Human Platelet Phenol Sulfotransferases
J. Biol. Chem., January 7, 2000; 275(1): 159 - 166.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. V. Petrotchenko, M. E. Doerflein, Y. Kakuta, L. C. Pedersen, and M. Negishi
Substrate Gating Confers Steroid Specificity to Estrogen Sulfotransferase
J. Biol. Chem., October 15, 1999; 274(42): 30019 - 30022.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.